Cantor Fitzgerald Raises United Therapeutics (NASDAQ:UTHR) Price Target to $625.00

United Therapeutics (NASDAQ:UTHR) had its price target boosted by investment analysts at Cantor Fitzgerald from $525.00 to $625.00 in a note issued to investors on Thursday, Marketbeat.com reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 16.58% from the company’s current price.

A number of other research analysts also recently commented on the company. Bank of America restated a “neutral” rating on shares of United Therapeutics in a research note on Wednesday, February 25th. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. UBS Group boosted their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a report on Thursday, March 5th. TD Cowen upped their price target on shares of United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Finally, Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $548.09.

United Therapeutics Stock Up 0.6%

Shares of UTHR stock opened at $536.12 on Thursday. The business has a 50 day moving average of $486.67 and a two-hundred day moving average of $460.13. United Therapeutics has a 52 week low of $266.98 and a 52 week high of $548.12. The company has a market cap of $23.50 billion, a P/E ratio of 19.22, a PEG ratio of 1.92 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating the consensus estimate of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business’s revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the company earned $6.19 earnings per share. Analysts expect that United Therapeutics will post 24.48 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Ray Kurzweil sold 4,910 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $489.02, for a total value of $2,401,088.20. Following the completion of the transaction, the director owned 12,670 shares in the company, valued at $6,195,883.40. This represents a 27.93% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $539.54, for a total transaction of $5,125,630.00. Following the sale, the chief executive officer owned 130 shares in the company, valued at $70,140.20. This trade represents a 98.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 338,947 shares of company stock valued at $165,516,573. Corporate insiders own 10.30% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors have recently added to or reduced their stakes in UTHR. Torren Management LLC bought a new position in United Therapeutics during the 4th quarter valued at $26,000. Activest Wealth Management increased its position in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC raised its stake in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. raised its stake in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares in the last quarter. Finally, Entrust Financial LLC acquired a new stake in shares of United Therapeutics in the fourth quarter valued at $31,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.